OncoMatch/Ovarian Cancer/Folate Receptor Alpha (FRα)
Ovarian CancerFolate Receptor Alpha (FRα) Clinical Trials
Folate receptor alpha (FRα, encoded by FOLR1) is overexpressed in the large majority of high-grade serous ovarian carcinomas and is an established therapeutic target. Mirvetuximab soravtansine, a FRα-directed ADC, received FDA accelerated approval for FRα-positive (IHC 2+ or 3+) platinum-resistant ovarian/fallopian tube/primary peritoneal cancer after 1–3 prior regimens (SORAYA trial), and subsequently full approval based on MIRASOL. Trials investigate mirvetuximab in earlier lines, combinations with bevacizumab or IO agents, and next-generation FRα-directed ADCs.
Top recruiting Folate Receptor Alpha (FRα) Ovarian Cancer trials
Ranked by phase and US site count.
See all trials matched to your profile →A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
AbbVie
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
University of Alabama at Birmingham
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
AbbVie
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
University of Colorado, Denver
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Beijing Biotech